Cargando…
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
In typical hemolytic uremic syndrome (HUS) approximately 25% of patients show central nervous system (CNS) involvement often leading to serious long-term disabilities. We used the C5-complement inhibitor Eculizumab as rescue therapy. From 2011 to 2014, 11 children (median age 22 months, range 11–175...
Autores principales: | Pape, Lars, Hartmann, Hans, Bange, Franz Christoph, Suerbaum, Sebastian, Bueltmann, Eva, Ahlenstiel-Grunow, Thurid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616562/ https://www.ncbi.nlm.nih.gov/pubmed/26091445 http://dx.doi.org/10.1097/MD.0000000000001000 |
Ejemplares similares
-
Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015) -
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011) -
Virus-specific T cells in pediatric renal transplantation
por: Ahlenstiel-Grunow, Thurid, et al.
Publicado: (2020) -
Correction to: Novel ways to monitor immunosuppression in pediatric kidney transplant recipients—underlying concepts and emerging data
por: Ahlenstiel-Grunow, Thurid, et al.
Publicado: (2021) -
Novel ways to monitor immunosuppression in pediatric kidney transplant recipients—underlying concepts and emerging data
por: Ahlenstiel-Grunow, Thurid, et al.
Publicado: (2021)